-Amryt Pharma said on Monday the U.S. Food and Drug Administration declined to approve the company’s drug for the treatment of a group of rare skin diseases called epidermolysis bullosa. The agency has asked Amryt to submit additional data confirming effectiveness of the drug. The decision comes after the FDA had extended its review of the treatment, oleogel-S10, in November by three months to review additional analyses of data previously submitted by the company. The regulator had also asked for new information on the drug. Amryt said it intends to discuss with the FDA regarding the nature of…